Targeting mitotic kinesin KIF20A: A differentiation-based therapeutic strategy for glioblastoma stem/progenitor cells.
Overview
- Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
- Division of Comparative Medicine, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
- Department of Hematology and Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratories, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
- Department of Diabetes & Cancer Metabolism, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
- Department of Radiation Oncology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
Abstract
Glioblastoma multiforme (GBM) remains refractory to current treatment modalities. Differentiation-based approaches, which force cancer stem/
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.
The paper's code and data availability statement is in the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.
Data
No dataset and no data link were found in the paper.
Data and code availability
• Any information required to reanalyze the data reported in this paper is available from the lead contact upon request. • This study does not report original code.
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 2, 28 September 2026
- Authors: added Qiang Lu (0000-0001-5753-9988); removed Qiang Lu
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 13 authors, 7 keywords, 12 MeSH terms, 2 funders, 34 references, 12 RRIDs.
Cite
This paper
Qiu, R., Ojeda, A. V., Gonzalez, C., Abatay, V., Wu, J., Awabdeh, D., Starr, R., Carlesso, N., Shuck, S., Li, Y. R., Brown, C. E., Barish, M. E., & Lu, Q. (2026). Targeting mitotic kinesin KIF20A: A differentiation-based therapeutic strategy for glioblastoma stem/
BibTeX
@article{qiu2026targetin
author = {Qiu, Runxiang and Ojeda, Alejandra Velazquez and Gonzalez, Cesar and Abatay, Vincente and Wu, Jun and Awabdeh, Dina and Starr, Renate and Carlesso, Nadia and Shuck, Sarah and Li, Yun Rose and Brown, Christine E. and Barish, Michael E. and Lu, Qiang},
title = {{Targeting mitotic kinesin KIF20A: A differentiation-based therapeutic strategy for glioblastoma stem/
journal = {Stem cell reports},
year = {2026},
month = jul,
volume = {21},
number = {8},
pages = {103013},
publisher = {Elsevier},
issn = {2213-6711},
doi = {10.1016/
url = {https://
pmid = {42462712},
pmcid = {PMC13476882}
}
RIS
TY - JOUR
AU - Qiu, Runxiang
AU - Ojeda, Alejandra Velazquez
AU - Gonzalez, Cesar
AU - Abatay, Vincente
AU - Wu, Jun
AU - Awabdeh, Dina
AU - Starr, Renate
AU - Carlesso, Nadia
AU - Shuck, Sarah
AU - Li, Yun Rose
AU - Brown, Christine E.
AU - Barish, Michael E.
AU - Lu, Qiang
TI - Targeting mitotic kinesin KIF20A: A differentiation-based therapeutic strategy for glioblastoma stem/
T2 - Stem cell reports
J2 - Stem Cell Reports
PY - 2026
DA - 2026/
VL - 21
IS - 8
SP - 103013
SN - 2213-6711
PB - Elsevier
DO - 10.1016/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1016/
"type": "article-journal",
"title": "Targeting mitotic kinesin KIF20A: A differentiation-based therapeutic strategy for glioblastoma stem/
"container-title": "Stem cell reports",
"author": [
{
"family": "Qiu",
"given": "Runxiang"
},
{
"family": "Ojeda",
"given": "Alejandra Velazquez"
},
{
"family": "Gonzalez",
"given": "Cesar"
},
{
"family": "Abatay",
"given": "Vincente"
},
{
"family": "Wu",
"given": "Jun"
},
{
"family": "Awabdeh",
"given": "Dina"
},
{
"family": "Starr",
"given": "Renate"
},
{
"family": "Carlesso",
"given": "Nadia"
},
{
"family": "Shuck",
"given": "Sarah"
},
{
"family": "Li",
"given": "Yun Rose"
},
{
"family": "Brown",
"given": "Christine E."
},
{
"family": "Barish",
"given": "Michael E."
},
{
"family": "Lu",
"given": "Qiang"
}
],
"container-title-short":
"volume": "21",
"issue": "8",
"page": "103013",
"DOI": "10.1016/
"PMID": "42462712",
"PMCID": "PMC13476882",
"ISSN": "2213-6711",
"publisher": "Elsevier",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
16
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.3390/cancers15184619
- Repurposing Clemastine to Target Glioblastoma Cell Stemness.Journal: CancersIn common: other condition, 9 references
- [2] doi:10.1093/neuonc/noab269
- Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.Journal: Neuro-oncologyIn common: other condition, 6 references
- [3] doi:10.1038/s41591-022-02141-2
- Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.Journal: Nature medicineIn common: other condition, 4 references
- [4] doi:10.3389/fonc.2023.1166207
- An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?Journal: Frontiers in oncologyIn common: other condition, 4 references
- [5] doi:10.1172/jci.insight.198298
- Development and characterization of triazole-based WDR5 inhibitors for the treatment of glioblastoma.Journal: JCI insightIn common: other condition, mouse, 4 references
- [6] doi:10.1038/s43856-025-00767-0 [code]
- The radiogenomic and spatiogenomic landscapes of glioblastoma and their relationship to oncogenic drivers.Journal: Communications medicineIn common: other condition, 5 references
- [7] doi:10.1186/s12885-024-13187-5
- Human stem cell models to unravel brain cancer.Journal: BMC cancerIn common: other condition, mouse, 4 references
- [8] doi:10.1016/j.stemcr.2025.102597
- Modeling glioma intratumoral heterogeneity with primary human neural stem and progenitor cells.Journal: Stem cell reportsIn common: other condition, mouse, 4 references
- [9] doi:10.1016/j.stemcr.2024.09.007
- Targeting glioblastoma with a brain-penetrant drug that impairs brain tumor stem cells via NLE1-Notch1 complex.Journal: Stem cell reportsIn common: other condition, mouse, 4 references
- [10] doi:10.1038/s41467-025-58366-5 [code]
- Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression.Journal: Nature communicationsIn common: other condition, mouse, 4 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
